All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Florida Cancer Specialists & Research Institute Breaks Ground for New Cancer Center in Wesley Chapel

October 12th 2022

Florida Cancer Specialists & Research Institute, LLC celebrated the groundbreaking for a new cancer center in Wesley Chapel at 30142 State Road 56, Wesley Chapel, Florida 33543.

Zanubrutinib Demonstrates PFS Benefit Vs Ibrutinib in Relapsed/Refractory CLL/SLL

October 12th 2022

Zanubrutinib produced a superior progression-free survival benefit compared with ibrutinib in previously treated patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to the final PFS analysis of the phase 3 ALPINE trial.

Expert Puts the Accent on Curative Potential in NSCLC Landscape

October 12th 2022

Mark A. Socinski, MD, has become internationally known for his research into the molecular drivers of lung cancer and his contributions to the refinement of multidisciplinary care.

Niraparib Maintenance Produces Long-Term Benefit in Advanced Ovarian Cancer, Irrespective of HRD Status

October 12th 2022

González-Martín discusses the updated long-term efficacy and safety data from the PRIMA study, the importance of utilizing PARP inhibitors in patients with homologous recombination–deficient tumors, and the benefit observed with niraparib in those with homologous recombination–proficient tumors.

TQB2450 Plus Anlotinib Elicits Antitumor Activity in Advanced Endometrial Cancer

October 11th 2022

The combination of TQB2450 plus anlotinib generated responses and showcased a manageable safety profile in patients with recurrent or metastatic advanced endometrial cancer, according to data from the phase 2 TQB2450 II 08 trial.

Checkpoint Inhibition Prevails as Frontline Standard in BRAF-Mutant Melanoma

October 11th 2022

Findings from the DREAMseq trial indicate that nivolumab plus ipilimumab should be administered prior to the combination of a BRAF and MEK inhibitor in patients with advanced BRAF-mutant melanoma.

FDA Grants Priority Review to Sacituzumab Govitecan for Pretreated HR+/HER2- Metastatic Breast Cancer

October 11th 2022

The FDA has accepted and granted priority review to a supplemental biologics license application for sacituzumab govitecan for the treatment of with unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer after endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting.

Patients With Non–Clear Cell RCC and Sarcomatoid Differentiation Have Inferior Outcomes to Systemic Therapy

October 11th 2022

Patients with non–clear cell renal cell carcinoma and sarcomatoid differentiation experience inferior outcomes to standard systemic therapy compared with those with clear cell disease.

Leading UPMC Hillman Cancer Researchers Named as Susan G. Komen® Scholars and Advisors

October 11th 2022

Adrian V. Lee, PhD, a leading breast cancer researcher at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine, will join the Susan G. Komen Scientific Advisory Board to help lead Komen’s overall research strategy and investments.

Socioeconomic Disparities Associated With Worse OS in Head and Neck Cutaneous Soft Tissue Sarcoma

October 11th 2022

R. Lor Randall, MD, FACS, discusses how disparities may lead to worse outcomes for patients diagnosed with head and neck cutaneous soft tissue sarcomas.

Cost Minimization Relies on Sequencing in Metastatic Breast Cancer

October 11th 2022

Sequencing complexities with chemotherapy-based regimens in metastatic breast cancer pose unique challenges for valuebased decision-making in routine practice.

Dostarlimab Elicits Survival Benefit in dMMR/MSI-H Advanced Endometrial Cancer

October 11th 2022

Single-agent dostarlimab-gxly produced progression-free survival and overall survival benefits in patients with advanced or recurrent mismatch repair–deficient/microsatellite instability–high endometrial cancer.

Frontline BR Plus ASCT and Maintenance Rituximab Demonstrates Activity in Transplant-Eligible MCL

October 10th 2022

Bendamustine plus rituximab followed by autologous stem cell transplant and maintenance rituximab led to comparable outcomes defined by progression-free survival and objective response rate compared with R-CHOP/R-DHAP and ASCT as induction therapy in patients with mantle cell lymphoma.

Nivolumab/Ipilimumab Generates Worse Responses in Patients With Metastatic Clear Cell RCC With Low Serum Iron

October 10th 2022

The combination of nivolumab and ipilimumab (Yervoy) was associated with worse clinical benefit in patients with metastatic clear cell renal cell carcinoma who have low serum iron compared with patients with normal/high serum iron.

Tivozanib Improves OS in Long-Term Responders in Relapsed/Refractory, Advanced RCC

October 10th 2022

Tivozanib demonstrated an improvement in overall survival compared with sorafenib in pretreated patients with advanced clear cell renal cell carcinoma, particularly in those who remained progression-free at 1 year and beyond.

Neil Palmisiano, MD, Appointed as Deputy Director of Phase 1 Therapeutics for Hematologic Malignancies at Rutgers Cancer Institute of New Jersey

October 10th 2022

Further enhancing its focus on providing outstanding, innovative and compassionate care for cancer patients, Rutgers Cancer Institute of New Jersey, the state’s leading cancer center and only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, are welcoming a new leader to its team of internationally recognized physicians and researchers.

Negative Trials Fail to Dampen Enthusiasm for Adjuvant, Combination Therapy in RCC

October 10th 2022

Toni K. Choueiri, MD, provides perspective on key research in renal cell carcinoma, including the first demonstration of benefit with triplet therapy in metastatic clear cell disease, the expansion of HIF-2α inhibition into the first line, and success with VEGF/immune-oncology approaches in the non–clear cell population.

Investigators Seek to Resolve the “Obesity Paradox” in Lung Cancer

October 10th 2022

Smoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.

Frontline Avelumab Maintenance Displays Long-Term Benefit in Advanced Urothelial Carcinoma

October 10th 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the results of the subgroup analysis in patients with urothelial carcinoma who received frontline avelumab maintenance for at least 12 months on the phase 3 JAVELIN Bladder 100 trial.

Gilteritinib Induces Encouraging Responses in Newly Diagnosed FLT3-Mutated AML

October 9th 2022

Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.